



June 12, 2014

Intra-Cellular Therapies to Present at Upcoming Scientific Conferences

NEW YORK, June 12, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will be presenting at the following upcoming scientific conferences:

- 54th American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held June 16-19, 2014, in Hollywood, FL; and
- 29th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress of Neuropsychopharmacology, to be held June 22-26, 2014, in Vancouver, Canada.

ASCP Presentation

Oral Presentation: "Advancing ITI-007: A Novel Product Candidate for the Treatment of Schizophrenia, Bipolar Disorder and Other Neuropsychiatric Indications". Kimberly Vanover, et al. To be presented during the Pharmaceutical Pipeline Session on Monday, June 16th from 2:00 P.M. to 4:00 P.M. ET. Location: Grand Ballroom, Westin Diplomat Hotel.

Dr. Vanover's presentation will summarize the clinical development program of ITI-007 to date.

CINP Presentations

Poster #LP-01-008: "From animals to human: ITI-007 preclinical data and its translation to safety and efficacy results in patients with schizophrenia and other neuropsychiatric diseases". To be presented on Monday, June 23 from 5:15 P.M. to 6:45 P.M. Local Time. Location: Vancouver Convention Centre; Hall B.

Poster #LP-01-008 will provide an overview of the EEG, PET and other early pharmacodynamic data to inform dose selection in the clinical development of ITI-007 and how such findings translated to clinical findings in patients with sleep maintenance insomnia and acutely exacerbated schizophrenia.

Poster #LP-01-016: "Mechanism of action of ITI-007: A novel therapy for the treatment of schizophrenia and related psychoses". To be presented on Monday, June 23 from 5:15 P.M. to 6:45 P.M. Local Time. Location: Vancouver Convention Centre; Hall B.

Poster #LP-01-016 will summarize the available preclinical in vitro and in vivo evidence supporting the proposed mechanism of action of ITI-007.

In addition, at the CINP congress, Lawrence Wennogle will provide an overview of the Company's phosphodiesterase inhibitors platform during his presentation titled: "Role of cyclic nucleotides in cognitive function in the brain". To be presented during the symposium "Coming of age for phosphodiesterase inhibitors as central nervous system therapeutics" on Monday, June 23 from 3:00 P.M. to 5:00 P.M. Local Time. Location: Vancouver Convention Centre; Room 10.

About Intra-Cellular Therapies

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS"). The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. In December 2013, the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase 2 clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia. This study showed a statistically significant improvement in symptoms associated with schizophrenia at the 60 mg dose on the trial's pre-specified primary endpoint and a favorable safety profile. The Company is exploring lower doses of ITI-007 for the treatment of behavioral disturbances in dementia and related disorders. ITI-007 is in a Phase 1/2 safety, tolerability and pharmacokinetic clinical study in elderly patients and in geriatric subjects with and without dementia. The Company is also utilizing its phosphodiesterase ("PDE") platform and other proprietary chemistry platforms to develop drugs for the treatment of cognitive deficits in schizophrenia and other CNS disorders. The Company has partnered its lead PDE1 compound, ITI-214, and backups from this platform with the Takeda Pharmaceutical Company. ITI-214 has finished the first Phase 1 clinical trial and is now in subsequent Phase 1 trials. The Company is also developing inhibitors against additional

targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as cardiovascular disease.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our belief that the profile of ITI-007 on measures related to movement disorders, metabolic, prolactin or cardiovascular signals compares favorably to other marketed antipsychotics. All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to the following: our current and planned clinical trials for ITI-007 and our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third-parties for development and commercialization of our product candidates; and the other risk factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

CONTACT: Juan Sanchez, M.D.

Vice President

Corporate Communications and

Investor Relations of Intra-Cellular Therapies, Inc.

212-923-3344

Burns McClellan, Inc.

Lisa Burns/Angeli Kolhatkar (Investors)

Justin Jackson (Media)

jjackson@burnsmc.com

212-213-0006



Source: Intra-Cellular Therapies, Inc.

News Provided by Acquire Media